HFpEF in the Elderly: Exercise-Based Immunomodulatory Interventions and New Strategies

Trends in Immunotherapy

Review Article

HFpEF in the Elderly: Exercise-Based Immunomodulatory Interventions and New Strategies

Downloads

https://doi.org/10.54963/ti.v10i1.1229
Rui Li, Ahmad Rashidi Mohd Tahir, Shairyzah Ahmad Hisham, & Siying Chen. (2026). HFpEF in the Elderly: Exercise-Based Immunomodulatory Interventions and New Strategies. Trends in Immunotherapy, 10(1), 43–57. https://doi.org/10.54963/ti.v10i1.1229
Volume 10, Issue 1 (March 2026): In Progress
Copyright (c) 2026 Rui Li, Ahmad Rashidi Mohd Tahir, Shairyzah Ahmad Hisham, Siying Chen
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Rui Li

    Faculty of Pharmacy, University of Cyberjaya, Persiaran Bestari, Cyber11, Cyberjaya 63000, Selangor, Malaysia
  • Ahmad Rashidi Mohd Tahir

    Faculty of Pharmacy, University of Cyberjaya, Persiaran Bestari, Cyber11, Cyberjaya 63000, Selangor, Malaysia
  • Shairyzah Ahmad Hisham

    Faculty of Pharmacy, University of Nottingham Malaysia, Jalan Broga, Semenyih 43500, Selangor, Malaysia
  • Siying Chen

    Department Radiology, The Second Affliated Hospital of Kunming Medical University, No.374 Dianmian street, Wuhua District, Kunming 650101, China

Received: 13 March 2025; Revised: 3 July 2025; Accepted: 29 July 2025; Published: 9 January 2026

To examine the immunopathological mechanisms underlying heart failure with preserved ejection fraction (HFpEF) in elderly patients and evaluate exercise training as an immunomodulatory intervention for managing disease complications. A narrative literature review was conducted using PubMed, Embase, and Cochrane Library databases (2010–2023), focusing on immune dysfunction, aging, and exercise interventions in HFpEF. HFpEF pathophysiology in elderly patients involves complex interactions between innate and adaptive immunity, characterized by elevated pro-inflammatory cytokines, NLRP3 inflammasome activation, and immune cell dysfunction. Major complications—frailty syndrome, sarcopenia, and malnutrition—share common inflammatory pathways that perpetuate disease progression. Exercise training fundamentally alters this inflammatory profile through multiple mechanisms: suppressing pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6), promoting anti-inflammatory immune cell phenotypes, and enhancing tissue regenerative capacity. Unlike pharmacological interventions targeting single pathways, exercise exerts pleiotropic effects across the immune-inflammatory network, simultaneously addressing cardiac dysfunction and systemic complications. Structured exercise programs effectively interrupt inflammatory cascades, improve functional capacity, and enhance quality of life in elderly HFpEF patients. Exercise training represents a cornerstone intervention that directly targets the fundamental immunopathology of HFpEF. Implementation of specialized exercise-based cardiac rehabilitation programs tailored to elderly patients is urgently needed to optimize clinical outcomes in this growing population.

Keywords:

Clinical Syndrome Complications Elderly Exercise Training HFpEF Immune Inflammation

References

  1. Savarese, G.; Stolfo, D.; Sinagra, G.; et al. Heart Failure with Mid-Range or Mildly Reduced Ejection Fraction. Nat. Rev. Cardiol. 2022, 19, 100–116.
  2. Duque, E.R.; Briasoulis, A.; Alvarez, P.A. Heart Failure with Preserved Ejection Fraction in the Elderly: Pathophysiology, Diagnostic and Therapeutic Approach. J. Geriatr. Cardiol. 2019, 16, 421.
  3. Reddy, Y.N.; Koepp, K.E.; Carter, R.; et al. Rate-Adaptive Atrial Pacing for Heart Failure with Preserved Ejection Fraction: The RAPID-HF Randomized Clinical Trial. JAMA 2023, 329, 801–809.
  4. Tromp, J.; Shen, L.; Jhund, P.S.; et al. Age-Related Characteristics and Outcomes of Patients with Heart Failure with Preserved Ejection Fraction. J. Am. Coll. Cardiol. 2019, 74, 601–612.
  5. Yang, Q.; Sun, Y.; Xing, Y.; et al. Frailty Prevalence and Associated Factors in Elderly Heart Failure Patients with Preserved Ejection Fraction. Chin. Gen. Pract. 2021, 24, 1354.
  6. Kittleson, M.M.; Panjrath, G.S.; Amancherla, K.; et al. ACC Expert Consensus Decision Pathway on Management of Heart Failure with Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J. Am. Coll. Cardiol. 2023, 81, 1835–1878.
  7. Paulus, W.J.; Zile, M.R. From Systemic Inflammation to Myocardial Fibrosis: The Heart Failure with Preserved Ejection Fraction Paradigm Revisited. Circ. Res. 2021, 128, 1451–1467.
  8. Schiattarella, G.G.; Altamirano, F.; Tong, D.; et al. Nitrosative Stress Drives Heart Failure with Preserved Ejection Fraction. Nature 2019, 568, 351–356.
  9. Sachdev, V.; Sharma, K.; Keteyian, S.J.; et al. Supervised Exercise Training for Chronic Heart Failure with Preserved Ejection Fraction: A Scientific Statement from the American Heart Association and American College of Cardiology. J. Am. Coll. Cardiol. 2023, 81, 1524–1542.
  10. Fang, J.; Wang, Z.; Yu, J. Advances in Pathophysiological Mechanisms and Therapeutic Efficacy of Exercise Rehabilitation in Patients with Heart Failure with Preserved Ejection Fraction. Front. Cardiovasc. Med. 2025, 12, 1598878.
  11. Glezeva, N.; Baugh, J. Role of Inflammation in the Pathogenesis of Heart Failure with Preserved Ejection Fraction and Its Potential as a Therapeutic Target. Heart Fail. Rev. 2014, 19, 681–694.
  12. Hanscombe, K.B.; Persyn, E.; Traylor, M.; et al. The Genetic Case for Cardiorespiratory Fitness as a Clinical Vital Sign and the Routine Prescription of Physical Activity in Healthcare. Genome Med. 2021, 13, 1–19.
  13. Lehto, T.; Zetterman, T.; Markkula, R.; et al. Cardiac Output and Arteriovenous Oxygen Difference Contribute to Lower Peak Oxygen Uptake in Patients with Fibromyalgia. BMC Musculoskelet. Disord. 2023, 24, 541.
  14. Bunsawat, K.; Nelson, M.D.; Hearon, C.M., et al. Exercise Intolerance in Heart Failure with Preserved Ejection Fraction: Causes, Consequences and the Journey towards a Cure. Exp. Physiol. 2024, 109, 502–512.
  15. Leuschner, F.; Nahrendorf, M. Novel Functions of Macrophages in the Heart: Insights into Electrical Conduction, Stress, and Diastolic Dysfunction. Eur. Heart J. 2020, 41, 989–994.
  16. Sanders-van Wijk, S.; Tromp, J.; Beussink-Nelson, L.; et al. Proteomic Evaluation of the Comorbidity–Inflammation Paradigm in Heart Failure with Preserved Ejection Fraction: Results from the PROMIS-HFpEF Study. Circ. 2020, 142, 2029–2044.
  17. Smolgovsky, S.; Bayer, A.L.; Kaur, K.; et al. Impaired T Cell IRE1α/XBP1 Signaling Directs Inflammation in Experimental Heart Failure with Preserved Ejection Fraction. J. Clin. Investig. 2023, 133, 24.
  18. Schiattarella, G.G.; Alcaide, P.; Condorelli, G.; et al. Immunometabolic Mechanisms of Heart Failure with Preserved Ejection Fraction. Nat. Cardiovasc. Res. 2022, 1, 211–222.
  19. Kim, S.R.; Lee, S.G.; Kim, S.H.; et al. SGLT2 Inhibition Modulates NLRP3 Inflammasome Activity via Ketones and Insulin in Diabetes with Cardiovascular Disease. Nat. Commun. 2020, 11, 2127.
  20. Sinan, Ü.Y.; Ekmekçi, A.; Özbay, B.; et al. The Real-Life Data of Hospitalized Patients with Heart Failure: On Behalf of the Journey HF-TR Study Investigators. Anatol. J. Cardiol. 2019, 21, 25–30.
  21. Conrad, N.; Judge, A.; Canoy, D.; et al. Temporal Trends and Patterns in Mortality after Incident Heart Failure: A Longitudinal Analysis of 86,000 Individuals. JAMA Cardiol. 2019, 4, 1102–1111.
  22. Sotomi, Y.; Hikoso, S.; Nakatani, D.; et al. Sex Differences in Heart Failure with Preserved Ejection Fraction. J. Am. Heart Assoc. 2021, 10, e018574.
  23. Redfield, M.M.; Borlaug, B.A. Heart Failure with Preserved Ejection Fraction: A Review. JAMA 2023, 329, 827–838.
  24. Albar, Z.H.; Zidar, D.A.; Al-Kindi, S.G. Inflammatory Markers and Risk of Heart Failure with Reduced, Mid-Range and Preserved Ejection Fraction. J. Card. Fail. 2020, 26, S16–S17.
  25. Mesquita, T.; Lin, Y.N.; Ibrahim, A. Chronic Low‐Grade Inflammation in Heart Failure with Preserved Ejection Fraction. Aging Cell 2021, 20, e13453.
  26. Everett, B.M.; Cornel, J.H.; Lainscak, M.; et al. Anti-Inflammatory Therapy with Canakinumab for the Prevention of Hospitalization for Heart Failure. Circ. 2019, 139, 1289–1299.
  27. Ding, N.; Shah, A.M.; Blaha, M.J.; et al. Cigarette Smoking, Cessation, and Risk of Heart Failure with Preserved and Reduced Ejection Fraction. J. Am. Coll. Cardiol. 2022, 79, 2298–2305.
  28. Wang, Q.; Lin, Z.; Zhou, Y.; et al. Effects of Smoking on Adverse Events in Patients with Heart Failure with Preserved Ejection Fraction. Chin. Gen. Pract. 2020, 23, 161.
  29. Kamimura, D.; Valle, K.A.; Blackshear, C.; et al. Relation of Low Normal Left Ventricular Ejection Fraction to Heart Failure Hospitalization in Blacks (From the Jackson Heart Study). Am. J. Cardiol. 2020, 136, 100–106.
  30. Lopez-Jimenez, F.; Almahmeed, W.; Bays, H.; et al. Obesity and Cardiovascular Disease: Mechanistic Insights and Management Strategies. A Joint Position Paper by the World Heart Federation and World Obesity Federation. Eur. J. Prev. Cardiol. 2022, 29, 2218–2237.
  31. Prenner, S.B.; Mather, P.J. Obesity and Heart Failure with Preserved Ejection Fraction: A Growing Problem. Trends Cardiovasc. Med. 2018, 28, 322–327.
  32. Nakamori, S.; Kucukseymen, S.; Rodriguez, J.; et al. Obesity-Related Differences in Pathomechanism and Outcomes in Patients with HFpEF: A CMR Study. JACC Adv. 2023, 2, 100730.
  33. Lee, H.; Lee, E.; Jang, I.Y. Frailty and Comprehensive Geriatric Assessment. J. Korean Med. Sci. 2020, 35, e16.
  34. Pandey, A.; Kitzman, D.; Reeves, G. Frailty Is Intertwined with Heart Failure: Mechanisms, Prevalence, Prognosis, Assessment, and Management. JACC Heart Fail. 2019, 7, 1001–1011.
  35. Sze, S.; Pellicori, P.; Zhang, J.; et al. Identification of Frailty in Chronic Heart Failure. JACC Heart Fail. 2019, 7, 291–302.
  36. Kaul, P.; Rathwell, S.; Lam, C.S.; et al. Patient-Reported Frailty and Functional Status in Heart Failure with Preserved Ejection Fraction: Insights from VITALITY-HFpEF. ESC Heart Fail. 2023, 11, 392–403.
  37. Aranda, J.F.; Ramírez, C.M.; Mittelbrunn, M. Inflammageing, a Targetable Pathway for Preventing Cardiovascular Diseases. Cardiovasc. Res. 2024, cvae240.
  38. Vitale, C.; Jankowska, E.; Hill, L.; et al. Heart Failure Association of the European Society of Cardiology Position Paper on Frailty in Patients with Heart Failure. Eur. J. Heart Fail. 2019, 21, 1299–1305.
  39. Annweiler, C.; Belmin, J.; Bouleti, C.; et al. Practical Management of Frailty in Older Patients with Heart Failure. ESC Heart Fail. 2022, 9, 4053–4064.
  40. Curcio, F.; Testa, G.; Liguori, I.; et al. Sarcopenia and Heart Failure. Nutrients 2020, 12, 211.
  41. Na, W.; Kim, J.; Chung, B.H.; et al. Relationship between Diet Quality and Sarcopenia in Elderly Koreans: 2008–2011 Korea National Health and Nutrition Examination Survey. Nutr. Res. Pract. 2020, 14, 352–364.
  42. Maeda, D.; Fujimoto, Y.; Nakade, T.; et al. Frailty, Sarcopenia, Cachexia, and Malnutrition in Heart Failure. Korean Circ. J. 2024, 54, 363–381.
  43. Yin, J.; Lu, X.; Qian, Z.; et al. New Insights into the Pathogenesis and Treatment of Sarcopenia in Chronic Heart Failure. Theranostics 2019, 9, 4019.
  44. Ali, M. Anticholinergic Adverse Effects in Older People. Masther thesis, Lithuanian University of Health Sciences, Kaunas, Lithuania, 26 February 2024.
  45. Schiattarella, G.G.; Rodolico, D.; Hill, J.A. Metabolic Inflammation in Heart Failure with Preserved Ejection Fraction. Cardiovasc. Res. 2021, 117, 423–434.
  46. Seo, J.H.; Lee, Y. Association of Physical Activity with Sarcopenia Evaluated Based on Muscle Mass and Strength in Older Adults: 2008–2011 and 2014–2018 Korea National Health and Nutrition Examination Surveys. BMC Geriatr. 2022, 22, 217.
  47. Witkowski, M.; Weeks, T.L.; Hazen, S.L. Gut Microbiota and Cardiovascular Disease. Circ. Res. 2020, 127, 553–570.
  48. Urgessa, M. Evaluation of the Mini Nutritional Assessment Short-Form [MNA-SF] as Compared to Serum Albumin Concentration in the Community Dwelling Elders, Meki, East Ethiopia. Asian J. Food Nutr. Athl. Enhanc. 2024.
  49. Nishi, I.; Seo, Y.; Hamada‐Harimura, Y.; et al. Geriatric Nutritional Risk Index Predicts All‐Cause Deaths in Heart Failure with Preserved Ejection Fraction. ESC Heart Fail. 2019, 6, 396–405.
  50. Siotto, M.; Germanotta, M.; Guerrini, A.; et al. Relationship between Nutritional Status, Food Consumption and Sarcopenia in Post-Stroke Rehabilitation: Preliminary Data. Nutrients 2022, 14, 4825.
  51. Edelmann, F.; Gelbrich, G.; Düngen, H.D.; et al. Exercise Training Improves Exercise Capacity and Diastolic Function in Patients with Heart Failure with Preserved Ejection Fraction: Results of the Ex-DHF (Exercise Training in Diastolic Heart Failure) Pilot Study. J. Am. Coll. Cardiol. 2011, 58, 1780–1791.
  52. Pandey, A.; Parashar, A.; Kumbhani, D.J.; et al. Exercise Training in Patients with Heart Failure and Preserved Ejection Fraction: Meta-Analysis of Randomized Control Trials. Circ. Heart Fail. 2015, 8, 33–40.
  53. Fukuta, H.; Goto, T.; Wakami, K.; et al. Effects of Drug and Exercise Intervention on Functional Capacity and Quality of Life in Heart Failure with Preserved Ejection Fraction: A Meta-Analysis of Randomized Controlled Trials. Eur. J. Prev. Cardiol. 2016, 23, 78–85.
  54. Nolte, K.; Herrmann-Lingen, C.; Wachter, R.; et al. Effects of Exercise Training on Different Quality of Life Dimensions in Heart Failure with Preserved Ejection Fraction: The Ex-DHF-P Trial. Eur. J. Prev. Cardiol. 2015, 22, 582–593.
  55. Baral, R.; Ho, J.S.Y.; Soroya, A.N.; et al. Exercise Training Improves Exercise Capacity and Quality of Life in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Eur. Heart J. Open 2024, 4, oeae033.
  56. Edelmann, F.; Wachter, R.; Duvinage, A.; et al. Combined Endurance and Resistance Exercise Training in Heart Failure with Preserved Ejection Fraction: A Randomized Controlled Trial. Nat. Med. 2025, 31, 306–314.
  57. Collao, N.; Rada, I.; Francaux, M.; et al. Anti-Inflammatory Effect of Exercise Mediated by Toll-Like Receptor Regulation in Innate Immune Cells—A Review. Int. Rev. Immunol. 2020, 39, 39–52.
  58. Severinsen, M.C.K.; Pedersen, B.K. Muscle–Organ Crosstalk: The Emerging Roles of Myokines. Endocr. Rev. 2020, 41, 594–609.
  59. Peh, Z.H.; Dihoum, A.; Hutton, D.; et al. Inflammation as a Therapeutic Target in Heart Failure with Preserved Ejection Fraction. Front. Cardiovasc. Med. 2023, 10, 1125687.
  60. Kessler, E.L.; Oerlemans, M.I.; van den Hoogen, P.; et al. Immunomodulation in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives. J. Cardiovasc. Transl. Res. 2021, 14, 63–74.
  61. Kemmler, W.; Kohl, M.; Fröhlich, M.; et al. Effects of High‐Intensity Resistance Training on Osteopenia and Sarcopenia Parameters in Older Men With Osteosarcopenia—One‐Year Results of the Randomized Controlled Franconian Osteopenia and Sarcopenia Trial (FrOST). J. Bone Miner. Res. 2020, 35, 1634–1644.
  62. Kataoka, R.; Hammert, W.B.; Yamada, Y.; et al. The Plateau in Muscle Growth With Resistance Training: An Exploration of Possible Mechanisms. Sports Med. 2024, 54, 31–48.
  63. Brubaker, P.H.; Nicklas, B.J.; Houston, D.K.; et al. A Randomized, Controlled Trial of Resistance Training Added to Caloric Restriction Plus Aerobic Exercise Training in Obese Heart Failure With Preserved Ejection Fraction. Circ. Heart Fail. 2023, 16, e010161.
  64. Quiriarte, H.; Noland, R.C.; Stampley, J.E.; et al. Exercise Therapy Rescues Skeletal Muscle Dysfunction and Exercise Intolerance in Cardiometabolic HFpEF. JACC Basic Transl. Sci. 2024, 9, 1409–1425.
  65. Ramírez-Vélez, R.; González, A.; García-Hermoso, A.; Aet al. Revisiting Skeletal Myopathy and Exercise Training in Heart Failure: Emerging Role of Myokines. Metabolism 2023, 138, 155348.
  66. Van Spall, H.G.; Lee, S.F.; Xie, F.; et al. Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure: The PACT-HF Randomized Clinical Trial. JAMA 2019, 321, 753–761.
  67. Balakrishnan, R.; Thurmond, D.C. Mechanisms by Which Skeletal Muscle Myokines Ameliorate Insulin Resistance. Int. J. Mol. Sci. 2022, 23, 4636.
  68. Cheng, D.; Zhang, Q.; Wang, Z.; et al. Association Between Sarcopenia and Its Components and Dependency in Activities of Daily Living in Patients on Hemodialysis. J. Ren. Nutr. 2021, 31, 397–402.